scholarly article | Q13442814 |
P50 | author | Darius Moradpour | Q28322833 |
Zoltán Kutalik | Q30435012 | ||
Laurent Abel | Q30503755 | ||
Markus H Heim | Q39188870 | ||
Etienne Patin | Q41561223 | ||
Stephanie Bibert | Q42761880 | ||
Thierry Poynard | Q43252014 | ||
Bertrand Nalpas | Q50737298 | ||
Pierre-Yves Bochud | Q50877821 | ||
Jean-François Dufour | Q61977955 | ||
Stanislas Pol | Q87747574 | ||
Gladys Martinetti | Q98684608 | ||
P2093 | author name string | Hans Hirsch | |
Marc Bourlière | |||
Francesco Negro | |||
Beat Müllhaupt | |||
Ioannis Theodorou | |||
Andreas Cerny | |||
Julien Guergnon | |||
Stephan Regenass | |||
Nicolas Goossens | |||
Swiss Hepatitis C Cohort Study Group | |||
Lorenz Kuske | |||
Raffaele Malinverni | |||
ANRS HC EP 26 Genoscan Study Group | |||
Guenter Dollenmaier | |||
Meri Gorgiewski | |||
Tillman Gerlach | |||
P2860 | cites work | IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex | Q24336912 |
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 | ||
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques | Q24630281 | ||
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity | Q24642027 | ||
Lambda interferon inhibits hepatitis B and C virus replication | Q27469456 | ||
Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesions | Q27480734 | ||
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma | Q28235086 | ||
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 | ||
Antitumor activity of IFN-lambda in murine tumor models | Q28585272 | ||
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. | Q31040495 | ||
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response | Q34116121 | ||
EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo | Q34647423 | ||
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation | Q36291657 | ||
Antitumor activity of type I and type III interferons in BNL hepatoma model | Q36425910 | ||
Review article: predicting response in hepatitis C virus therapy | Q36447562 | ||
What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? | Q37389916 | ||
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). | Q40166878 | ||
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics | Q40211546 | ||
In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C. | Q42983312 | ||
Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. | Q42988942 | ||
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. | Q42990025 | ||
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection | Q42997865 | ||
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. | Q42997975 | ||
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis | Q43033159 | ||
Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). | Q43039935 | ||
The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection | Q43042435 | ||
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy | Q43049563 | ||
Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents | Q43251298 | ||
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa | Q43279592 | ||
Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. | Q43836377 | ||
Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. | Q44598567 | ||
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection | Q44703198 | ||
Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection | Q45510333 | ||
Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection | Q57160250 | ||
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC | Q58493937 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatitis C | Q154869 |
Hepatitis C virus | Q708693 | ||
P304 | page(s) | 384-394 | |
P577 | publication date | 2011-12-16 | |
P1433 | published in | Hepatology | Q15724398 |
P1476 | title | IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes | |
P478 | volume | 55 |